16-Mar-2021 - Technische Universität Carolo-Wilhelmina zu Braunschweig

New Chance for Better Pandemic Response

Researchers succeed in developing neutralizing anti-SARS-CoV-2 antibodies from immune cells of healthy donors

An international research team of the Technische Universität Braunschweig and the Helmholtz Centre for Infection Research (HZI), led by the Department of Biotechnology of the TU Braunschweig, has reported on the development of special antibodies against SARS-CoV-2 in the journal Nature Communications. These antibodies prevent the viruses from entering host cells and were isolated from an antibody gene library that had already been produced from immune cells of healthy donors before the pandemic. The study shows how, in the future, active substances to previously unknown, emerging viruses can be produced very quickly without patient material.

The research team from the TU Braunschweig and the HZI succeeded in generating the antibodies to SARS-CoV-2 in vitro using antibody phage display technology. This was based on the existing HAL9/10 antibody gene library, and for the best-performing antibodies, the researchers additionally mapped the binding sites to the virus and modeled the corresponding molecular interaction structure.

“This project would not have been possible without the truly extraordinary efforts of everyone on the team during the first months of the pandemic”, says Professor Michael Hust from the Department of Biotechnology, who initiated the project back in January 2020. “In addition to the potential use of the isolated antibodies against SARS-CoV-2, this study demonstrates a method for generating active agents against previously unknown, emerging viruses very quickly in the future without patient material.” Especially with pathogens from distant parts of the world, he said, this could mean a decisive head start in the fight against a pandemic, as researchers could begin work on an active agent before the first cases occur in Europe. The researchers at TU Braunschweig, in collaboration with the HZI and other partners, are therefore proposing to build a precautionary infrastructure to ward off future pandemics.

“To be better equipped against future pandemics, it is essential to establish long-term structures in research and development”, says Professor Dirk Heinz, Scientific Director of the HZI, in whose high-security laboratory the activity of antibodies against SARS-CoV-2 was detected. “A national platform for antiviral agents would be ideal, and we are currently working with partners to design one. The successful work on the antibodies shows – especially in times of limited mobility – the value of close collaboration between the highly committed partners on our research campus. In doing so, we have shown that Braunschweig can make another important contribution to pandemic response.”

Professor Luka Cicin-Sain and Dr. Ulfert Rand, head and scientist of the Immune Aging and Chronic Infections Research Group at the HZI, are very pleased with the results of the study. “It was a great moment when we saw in the experiment that the antibodies could actually prevent infection with SARS-CoV-2. We immediately realized that we had a potential weapon against the pandemic in our hands”, says Ulfert Rand. Cicin-Sain adds, “Ulfert Rand developed the methods for measuring the antibodies’ antiviral activity in record time. Overall, many scientists in our group and at the HZI supported us, making for a distinct team success.”

Dr. Maren Schubert from the Department of Biotechnology at TU Braunschweig, who was instrumental in accelerating the work through a new method she developed for producing the new viral components in insect cells: “We are very happy that our project has the potential to mitigate the Corona pandemic and save human lives. But it will also allow us to prepare much faster against future threats.”

Professor Stefan Dübel, head of the Department of Biotechnology at TU Braunschweig and one of the inventors of the method of antibody phage display which allowed the very rapid antibody generation, adds: “With this study, we have shown how we can take faster and more effective action against future epidemics of previously unknown infectious diseases than was previously possible – even if they have not yet reached us from distant parts of the world. This has given us a new option to better counter global spread in the future, as we painfully experienced with SARS-CoV-2.”

Facts, background information, dossiers

  • antibodies
  • SARS-CoV-2
  • antibody-phage display
  • phage display
  • coronaviruses

More about TU Braunschweig

  • News

    New Drug Candidates from Known Compounds

    The need for new drugs is high. Researchers at Technische Universität Braunschweig , together with colleagues from other universities, have presented a new platform for drug repurposing. This platform facilitates the search for new therapeutics. The results were published in the journal Nat ... more

    New Drug Grips Tumor Cells with Two Arms

    The first patients with advanced tumors have been treated with a novel antibody-based in a clinical trial in the USA. It uses an invention of the Technische Universität Braunschweig: The team of Professor Stefan Dübel, head of the Department of Biotechnology, discovered a human antibody tha ... more

    Luminous Molecules

    Many people know the effect from discos when “black light” makes clothes or writing boards glow. The reason for this are so-called fluorescent dyes. They send back part of the light they are exposed to in a slightly different way and thus glow. Particularly large fluorescent molecules are o ... more

More about Helmholtz-Zentrum für Infektionsforschung

  • News

    Two bugs with one stone

    The development of new active substances against pathogenic bacteria, parasites, fungi and viruses is gaining importance, as established antiinfectives are becoming increasingly ineffective due to the development of resistance. At the Helmholtz Institute for Pharmaceutical Research Saarland ... more

    New “decision aid” for CRISPR immune responses

    Friend or foe? Immune systems constantly face this question. They must recognize and clear foreign invaders without eliciting autoimmunity. Prokaryotic CRISPR-Cas systems recognize invaders based on genetic sequence. But what happens if the host genome shares the same sequences? A research ... more

    A precision cut for the CRISPR-Cas genetic scissors

    The nuclease Cas13b associated with CRISPR defense systems—also known as genetic scissors—has the potential to be used in the future in hereditary diseases to silence adverse genes. In the fight against infections, it is also being researched as an antiviral agent, as Cas13b can target the ... more

  • q&more articles

    Antibiotic resistance

    Do you also find it tiresome and disagreeable when tasks long-since done and dusted suddenly resurface, appear never to have been finished in the first place and now need your urgent attention? In drug research, the topic of antibiotics is a shining – and simultaneously appalling – example ... more

  • Authors

    Prof. Dr. Mark Brönstrup

    studied Chemistry at Philipps University Marburg (Germany) and London’s Imperial College. He obtained his doctorate in organic chemistry in 1999 from TU Berlin. From 2000 to 2013, he worked at the pharmaceutical company Sanofi in Frankfurt, first as head of a mass spectrometry lab before mo ... more

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by: